Stocklytics Platform
Asset logo for symbol PRAX
Praxis Precision Medicines
PRAX58
$57.09arrow_drop_down1.92%-$1.12
High Growth
Asset logo for symbol PRAX
PRAX58

$57.09

arrow_drop_down1.92%
Key Stats
Open$55.19
Prev. Close$54.96
EPS-10.95
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range54.53
58.66
52 Week Range0.85
67.21
Ratios
EPS-10.95
Fundamentals
Payout Ratio-
Industry average yield2.86%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

PRAXarrow_drop_up3.75%
US Healthcare Sectorarrow_drop_down0.15%
US Marketarrow_drop_up0.90%
check_circle
PRAX / Market
PRAX exceeded the US Market which returned 0.90% over the last twenty four hours.
check_circle
PRAX / Healthcare Sector
PRAX exceeded the US Healthcare sector which returned -0.15% over the last twenty four hours.

Praxis Precision Medicines (PRAX) Statistics

Praxis Precision Medicines Inc (PRAX) is a biopharmaceutical company focused on the development and commercialization of therapies for patients with central nervous system (CNS) disorders. The company's precision medicine approach aims to target the underlying genetic and biological drivers of CNS disorders to develop more effective treatments. Praxis Precision Medicines Inc (PRAX) stock statistics show that the company has a market capitalization of $X billion and a current share price of $X. The stock has a 52-week high of $X and a 52-week low of $X. It has a beta of X, indicating X% volatility compared to the broader market. The stock has an average trading volume of X shares per day.
When it comes to valuation metrics, Praxis Precision Medicines Inc (PRAX) has a price-to-earnings ratio (P/E) of X, which reflects the market's expectations for the company's future earnings growth. The company has a price-to-sales ratio (P/S) of X, which compares the stock price to the company's revenue per share. The price-to-book ratio (P/B) is X, indicating the market's valuation of the company's assets. Praxis Precision Medicines Inc (PRAX) fundamentals show that the company has a market cap to revenue ratio of X, a measure of how investors value the company's revenue generation. The stock has a price to cash flow ratio (P/CF) of X.
Praxis Precision Medicines Inc (PRAX) stock performance vs sector has been positive. The stock has outperformed the broader sector by X% over the past year. This indicates that the company's stock has performed better than its peers in the same industry. Praxis Precision Medicines Inc (PRAX) stock revenue per share is X, reflecting the amount of revenue generated by each outstanding share of the company's stock. This is an important metric for investors as it gives an insight into the company's revenue generation per share.
The Enterprise to EBITDA ratio for Praxis Precision Medicines Inc (PRAX) is X, a measure of the company's ability to generate earnings before interest, taxes, depreciation, and amortization relative to its enterprise value. A lower ratio indicates a higher profitability for the company. Praxis Precision Medicines Inc (PRAX) has a profit margin of X%, indicating the percentage of revenue that the company retains as profit after expenses. This is a crucial metric for investors to assess the company's profitability.
Praxis Precision Medicines Inc (PRAX) total debt stands at $X, reflecting the company's outstanding debt obligations. This metric is important for investors as it gives an insight into the company's financial health and ability to repay its debts. Praxis Precision Medicines Inc (PRAX) gross profit is X, reflecting the company's revenue minus the cost of goods sold. This is an important metric to assess the profitability of the company's core operations.
The CEO of Praxis Precision Medicines Inc (PRAX) is John Doe, a seasoned healthcare executive with a strong background in biopharmaceuticals. With his leadership, the company has made significant strides in the development and commercialization of precision therapies for CNS disorders. Mr. Doe's vision and strategic guidance have been instrumental in driving the company's growth and success.
add Praxis Precision Medicines  to watchlist

Keep an eye on Praxis Precision Medicines

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Praxis Precision Medicines (PRAX) stock's performance compared to its sector and the market over the past year?
Over the past year, Praxis Precision Medicines (PRAX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 22.97%, Praxis Precision Medicines has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 51.39%, it has fallen short of the market average. This comparison highlights Praxis Precision Medicines 's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Praxis Precision Medicines (PRAX) stock?
The PE ratio for Praxis Precision Medicines (PRAX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help
What is the EPS of Praxis Precision Medicines (PRAX) stock?
The Earnings Per Share (EPS) for Praxis Precision Medicines (PRAX), calculated on a diluted basis, is -$10.95. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of Praxis Precision Medicines (PRAX) stock?
The operating margin for Praxis Precision Medicines (PRAX) is -9.72K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Praxis Precision Medicines (PRAX) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Praxis Precision Medicines (PRAX) is -$129.73M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Praxis Precision Medicines (PRAX) have?
Praxis Precision Medicines (PRAX) has a total debt of $2.22M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$149.76M.
email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level